A study led by researchers at RCSI's Department of Chemistry has the potential to help surgeons more accurately remove tumors and detect cancer in lymph nodes during surgery. The research, led by RCSI professor of chemistry Donal O'Shea, has been published in Chemical Science.

Bringing together expertise in chemistry and biotechnology, the research team has identified the potential benefit of fluorescence imaging as a way of detecting cancer cells during surgery, developing a probe that lights up when it detects cancer.

According to O'Shea, "This is a very significant development, which has the potential to transform the surgical management of cancer, improving outcomes for patients. Almost 60% of all cancer patients will undergo surgery as part of their treatment."

"A new technology that could improve surgical outcomes by giving the surgical team real-time, informative images during the surgical procedure would have a wide-ranging and sustained impact on the care of cancer patients."

Addressing the next steps, O'Shea said, "At the moment, this is science. A clinical trial is our next goal, and that would allow the full potential of this discovery to be realized for patients, enhancing detection of life-threatening diseases and improving outcomes of surgical procedures."

The team has recently secured funding for a project on colorectal cancer diagnosis and treatment under the Project Ireland 2040 Disruptive Technology Innovation Fund in collaboration with leading cancer surgeon professor Ronan Cahill in the Mater University Hospital, UCD, and Dublin-based industry partners IBM-research and Deciphex.

The project will look at combining tissue-responsive probes, artificial intelligence, and machine learning to transform medical care for colorectal cancer patients.